{
    "Trade/Device Name(s)": [
        "Quantia Lp(a)",
        "Quantia Lp(a) Control",
        "Quantia Lp(a) Standard"
    ],
    "Submitter Information": "Biokit S.A.",
    "510(k) Number": "K050487",
    "Predicate Device Reference 510(k) Number(s)": [
        "K013128"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DFC",
        "JIS",
        "JJX"
    ],
    "Summary Letter Date": "April 26, 2005",
    "Summary Letter Received Date": "February 25, 2005",
    "Submission Date": "February 22, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.5600"
    ],
    "Regulation Name(s)": [
        "Low-density lipoprotein immunological test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Lipoprotein(a) [Lp(a)]"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Heparin tube",
        "Citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Clinical Chemistry Systems",
        "Abbott AEROSET"
    ],
    "Method(s)/Technology(ies)": [
        "Latex particle enhanced immunoturbidimetric assay",
        "Turbidimetry"
    ],
    "Methodologies": [
        "Immunoturbidimetric assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "Standard"
    ],
    "Document Summary": "FDA 510(k) summary for Quantia Lp(a) immunoturbidimetric assay for quantitative determination of lipoprotein(a) in human serum or plasma.",
    "Indications for Use Summary": "In vitro quantitative determination of lipoprotein(a) [Lp(a)] concentration in human serum or plasma to evaluate lipid metabolism disorders and assess atherosclerotic cardiovascular diseases, with Control and Standard for QC and calibration.",
    "fda_folder": "Immunology"
}